{"title":"Dosing of ACTS","nid":756,"vid":4259,"created":1622111432,"changed":1626692357,"field_accordian_header":[{"field_accordian":[{"field_title":"Revised dose recommendation for dihydroartemisinin + piperaquine in young children:&nbsp;","field_content":"<p><strong>Revised dose recommendation for dihydroartemisinin + piperaquine in young children:&nbsp;<\/strong>Children weighing &lt;25kg treated with dihydroartemisinin + piperaquine should receive a minimum of 2.5 mg\/kg bw per day of dihydroartemisinin and 20 mg\/ kg bw per day of piperaquine daily for 3 days.<\/p>\n\n<p class=\"statement\" style=\"background-color:rgb( 102 , 204 , 0 );  padding-left: 15px; padding-right: 15px; padding-top: 8px; padding-bottom: 5px;\"><span style=\"color:#ffffff\"><em>Strong recommendation*<\/em><\/span><\/p><\/tbody>\n\n<p>*unGRADEd recommendation, anticipated to be updated in 2021<\/p>\n","justification":"<p><span style=\"font-size:14px\">The dosing subgroup reviewed all available dihydroartemisinin-piperaquine pharmacokinetic data (6 published studies and 10 studies from the WWARN database; total 652 patients)&nbsp;<span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"10.1038\/clpt.2011.254\" data-label=\"\" data-pmid=\"22258469\" data-ref-id=\"362642\" data-url=\"\">[111]<\/cite><\/span><span class=\"magic-ref\"><cite class=\"magic-cite\" data-doi=\"10.1371\/journal.pmed.1001564\" data-label=\"\" data-pmid=\"24311989\" data-ref-id=\"362720\" data-url=\"\">[112]<\/cite><\/span> and then conducted simulations of piperaquine exposures for each weight group. These showed lower exposure in younger children with higher risks of treatment failure. The revised dose regimens are predicted to provide equivalent piperaquine exposures across all age groups.<br>\n<br>\n<strong>Other considerations<\/strong><br>\nThis dose adjustment is not predicted to result in higher peak piperaquine concentrations than in older children and adults, and as there is no evidence of increased toxicity in young children, the GRC concluded that the predicted benefits of improved antimalarial exposure are not at the expense of increased risk.<\/span><\/p>\n","practical_info":"<p><span style=\"font-size:14px\">Formulations: Currently available as a fixed-dose combination in tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine and paediatric tablets contain 20 mg dihydroartemisinin and 160 mg piperaquine.<br>\n<br>\nTarget dose and range:<em> <\/em>A target dose (range) of 4 (2\u201310) mg\/kg bw per day dihydroartemisinin and 18 (16\u201327) mg\/kg bw per day piperaquine given once a day for 3 days for adults and children weighing \u2265 25 kg. The target doses and ranges for children weighing &lt; 25 kg are 4 (2.5\u201310) mg\/kg bw per day dihydroartemisinin and 24 (20\u201332) mg\/kg bw per day piperaquine once a day for 3 days.<br>\n<br>\nRecommended dosage regimen:<em> <\/em>The dose regimen currently recommended by the manufacturer provides adequate exposure to piperaquine and excellent cure rates (&gt; 95%), except in children &lt; 5 years, who have a threefold increased risk for treatment failure. Children in this age group have significantly lower plasma piperaquine concentrations than older children and adults given the same mg\/kg bw dose. Children weighing &lt; 25 kg should receive at least 2.5 mg\/kg bw dihydroartemisinin and 20 mg\/kg bw piperaquine to achieve the same exposure as children weighing \u2265 25 kg and adults.<\/span><\/p>\n\n<p><span style=\"font-size:14px\">Dihydroartemisinin + piperaquine should be given daily for 3 days.<\/span><\/p>\n\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"width:100%\"><tbody><tr><td style=\"height:41px;width:110px;background-color:rgb( 102 , 204 , 255 )\">\n\t\t\t<p><span style=\"color:#0000ff\"><span style=\"font-size:14px\">Body weight (kg)<\/span><\/span><\/p>\n\t\t\t<\/td><td style=\"height:41px;width:214px;background-color:rgb( 102 , 204 , 255 )\">\n\t\t\t<p><span style=\"color:#0000ff\"><span style=\"font-size:14px\">Dihydroartemisinin + piperaquine dose (mg) given daily for 3 days<\/span><\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">5 to &lt; 8<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">20 + 160<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">8 to &lt; 11<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">30 + 240<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">11 to &lt; 17<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">40 + 320<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">17 to &lt; 25<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">60 + 480<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">25 to &lt; 36<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">80 + 640<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">36 to &lt; 60<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">120 + 960<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">60 &lt; 80<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">160 + 1280<\/span><\/p>\n\t\t\t<\/td><\/tr><tr><td style=\"height:24px;width:110px\">\n\t\t\t<p><span style=\"font-size:14px\">&gt;80<\/span><\/p>\n\t\t\t<\/td><td style=\"height:24px;width:214px\">\n\t\t\t<p><span style=\"font-size:14px\">200 + 1600<\/span><\/p>\n\t\t\t<\/td><\/tr><\/tbody><\/table>\n\n<p><span style=\"font-size:14px\">&nbsp;<br>\nFactors associated with altered drug exposure and treatment response:<\/span><\/p>\n\n<p><span style=\"font-size:14px\">High-fat meals should be avoided, as they significantly accelerate the absorption of piperaquine, thereby increasing the risk for potentially arrhythmogenic delayed ventricular repolarization (prolongation of the corrected electrocardiogram QT interval). Normal meals do not alter the absorption of piperaquine.<\/span><\/p>\n\u200b\u200b<span style=\"font-size:14px\">As malnourished children are at increased risk for treatment failure, their response to treatment should be monitored closely.<\/span>\n\n<ul><li><span style=\"font-size:14px\">Dihydroartemisinin exposure is lower in pregnant women.<\/span><\/li><li><span style=\"font-size:14px\">Piperaquine is eliminated more rapidly by pregnant women, shortening the post-treatment prophylactic effect of dihydroartemisinin + piperaquine. As this does not affect primary efficacy, no dosage adjustment is recommended for pregnant women.<\/span><\/li><\/ul>\n\n<p><br>\n<span style=\"font-size:14px\">Additional comments: Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. It is not necessary to perform an electrocardiogram before prescribing dihydroartemisinin + piperaquine, but this ACT should not be used in patients with congenital QT prolongation or who have a clinical condition or are on medications that prolong the QT interval. There has been no evidence of cardiotoxicity in large randomized trials or in extensive deployment.<\/span><\/p>\n","field_icon":null}],"field_header":"Revised dose recommendation for dihydroartemisinin + piperaquine in young children:&nbsp;"}],"field_content_type":{"tid":9,"name":"Accord","class":"accord"},"field_left_right_navigation":1,"field_operational_":[{"field_image":"","field_link":"","field_title":null}],"field_recommendations":1,"recommendation":"<p>All cases of suspected malaria should have a parasitological test (microscopy or Rapid diagnostic test (RDT)) to confirm the diagnosis.<br \/>\r\nBoth microscopy and RDTs should be supported by a quality assurance programme.<br \/>\r\n<font color=\"#4090CF\"><em>Good practice statement<\/em><\/font><\/p>\r\n","recommendation_title":"Rapid diagnostic test (RDT)","field_recommendation_api_url":"https:\/\/api.magicapp.org\/api\/v1\/recommendations\/?sectionId=78099","field_references":null,"field_tags":[{"tid":66,"name":"Recommendations for case management"},{"tid":47,"name":"Uncomplicated malaria"}]}